Public Employees Retirement Association of Colorado Acquires 44,000 Shares of Insulet Corporation $PODD

Public Employees Retirement Association of Colorado boosted its holdings in Insulet Corporation (NASDAQ:PODD) by 643.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,840 shares of the medical instruments supplier’s stock after acquiring an additional 44,000 shares during the quarter. Public Employees Retirement Association of Colorado owned 0.07% of Insulet worth $14,451,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Larson Financial Group LLC increased its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. Elyxium Wealth LLC bought a new stake in Insulet in the fourth quarter valued at about $28,000. Fideuram Asset Management Ireland dac bought a new stake in Insulet in the fourth quarter valued at about $41,000. Measured Wealth Private Client Group LLC bought a new stake in Insulet in the third quarter valued at about $49,000. Finally, Osterweis Capital Management Inc. bought a new stake in Insulet during the second quarter worth about $51,000.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.36% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Benchmark reaffirmed a “buy” rating on shares of Insulet in a research note on Wednesday, May 27th. Sanford C. Bernstein decreased their price objective on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. TD Cowen decreased their price objective on shares of Insulet from $379.00 to $294.00 and set a “hold” rating on the stock in a research note on Monday, June 1st. Stifel Nicolaus decreased their price objective on shares of Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Finally, Bank of America decreased their price objective on shares of Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $240.78.

Insulet Price Performance

PODD opened at $148.14 on Tuesday. Insulet Corporation has a one year low of $140.63 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The company’s 50 day simple moving average is $168.80 and its 200-day simple moving average is $230.66. The stock has a market capitalization of $10.26 billion, a P/E ratio of 34.45, a price-to-earnings-growth ratio of 1.18 and a beta of 1.13.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same period in the prior year, the firm earned $1.02 earnings per share. Insulet’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts anticipate that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.